Efficacy and Tolerability of RAP-219, a Potential First-in-class Negative Allosteric Modulator of γ8 Transmembrane AMPA Receptor Regulatory Protein: Impact on RNS Long Episodes and Clinical Seizures (S29.003)
William Motley, Imran Quraishi, Neal Nolan, Daniel Friedman, Patrick Landazuri, Vikram Rao, Kathryn Davis, Bradley Galer, Nancy Wyant, Martha Morrell, Arnold Gammaitoni, Jacqueline French
原始摘要（英文原文）· Original abstract
Assess the effect of RAP-219, a selective and potent transmembrane AMPA receptor regulatory protein (TARP)-γ8 negative allosteric modulator, using a novel biomarker (long episodes [LEs]) in patients with an implanted responsive neurostimulator (RNS® System, NeuroPace) for drug-resistant focal seizures (FOS).
Efficacy and Tolerability of RAP-219, a Potential First-in-class Negative Allosteric Modulator of γ8 Transmembrane AMPA Receptor Regulatory Protein: Impact on RNS Long Episodes and Clinical Seizures (S29.003) — 科研速览 Science Skim